EODData

MEMBERSHIP REGISTER LOG IN

FRA, 1ZLB: ZAI LAB LTD0000006

03 Feb 2026
LAST:

1.430

CHANGE:
 0.07		OPEN:
1.390		HIGH:
1.430		ASK:
0.000		VOLUME:
1.4K
CHG(%):
5.15		PREV:
1.360		LOW:
1.390		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Feb 261.3901.4301.3901.4301.4K
02 Feb 261.3101.3601.3101.3600
30 Jan 261.3801.4001.3801.4001.4K
29 Jan 261.4201.4501.4201.4201.4K
28 Jan 261.4401.4701.4401.4701.4K
27 Jan 261.4501.5001.4501.500958
26 Jan 261.4601.5001.4601.500958
23 Jan 261.5201.5501.5201.550958
22 Jan 261.5401.6001.5401.590958
21 Jan 261.5901.6201.5901.620958

PROFILE

Name:ZAI LAB LTD0000006
About:Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building B, Pudong, China, 201203
Website:https://www.zailaboratory.com
ISIN:KYG9887T1168

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.46 
PEG Ratio:0.17 
Price to Sales:3.57 
Price to Book:0.24 
Profit Margin:-0.47 
Operating Margin:-0.42 
Return on Assets:-0.13 
Return on Equity:-0.29 
Revenue:374.74M 
Shares:1.113B 
Market Cap:1.591B 

TECHNICAL INDICATORS

MA5:1.421.0%
MA10:1.483.8%
MA20:1.558.4%
MA50:1.5810.8%
MA100:2.0241.5%
MA200:2.4671.8%
STO9:29.17
STO14:24.14
RSI14:22.00 
WPR14:-75.86
MTM14:-0.22
ROC14:-0.13 
ATR:0.07 
Week High:1.504.9%
Week Low:1.319.2%
Month High:1.7119.6%
Month Low:1.3171.8%
Year High:3.66155.7%
Year Low:1.319.2%
Volatility:17.00